Drug updated on 3/28/2024
| Dosage Form | Tablet (oral: 50 mg, 100 mg) |
| Drug Class | Serotonin 1F receptor agonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the acute treatment of migraine with or without aura in adults.
Summary
- Lasmiditan (Reyvow) is indicated for the acute treatment of migraine with or without aura in adults.
- A total of 13 systematic reviews/meta-analyses were reviewed to gather information about Reyvow's safety and effectiveness.
- Compared to placebo, lasmiditan showed a significantly higher percentage of patients achieving pain freedom, sustained pain freedom, headache response, clinical disability level improvement and lower use of rescue medication.
- When compared to rimegepant and ubrogepant, lasmiditan demonstrated superior two-hour pain freedom but was inferior in terms of overall efficacy rates; however it did show some advantages such as early onset efficacy endpoints including relief at 1 hour and pain freedom at 2 hours.
- Despite its effectiveness in treating acute migraines across different doses (50mg -200mg), lasmiditan was associated with a higher likelihood adverse effects like dizziness, nausea and somnolence when compared both to placebo as well as other drugs like rimegepant and ubrogepant.
- Among all the drugs studied for comparison – Reyvow had the highest risk profile especially concerning neurological events such as dizziness & sedation which were mostly mild or moderate severity-wise; Rimegepant & Ubrogopent exhibited better tolerability profiles than Reyvow with Ubrogopent showing best overall tolerability profile among them all.
- Unlike triptans that have vasoconstrictive concerns related their usage – no significant cardiovascular-related Treatment-Emergent Adverse Events (TEAEs) were associated with Lasmitidan making it potentially safer option for patients having cardiovascular risk factors.
- Subgroup analysis based on specific population types beyond general adult population suffering from migraine wasn't extensively covered by these studys indicating data gap regarding tailored patient subgroup considerations.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Reyvow (lasmiditan) Prescribing Information. | 2022 | Lilly USA, LLC, Indianapolis, IN |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Va/DoD Clinical Practice Guideline for the primary care management of headache. | 2020 | U.S. Department of Veterans Affairs Department of Defense |